

Ozempic and Other Weight Loss Drugs Linked to 162 US Deaths

By [Dr. Joseph Mercola](#)

Global Research, November 05, 2024

[Mercola](#)

Region: [USA](#)

Theme: [Science and Medicine](#)

Ozempic and similar weight loss drugs have been linked to 162 deaths in the U.S., with adverse reactions increasing by 40% in six months as usage expands

These medications are associated with serious side effects, including pancreatitis, bowel obstruction and stomach paralysis, with 80% to 90% of users experiencing at least one adverse event

Studies have found a significant link between semaglutide (the active ingredient in Ozempic) and suicidal ideation, particularly in patients also taking antidepressants or anti-anxiety medications

Emerging reports indicate severe kidney problems in some patients using these weight loss drugs

Akkermansia, a beneficial gut bacteria, is a natural alternative to stimulate GLP-1 production, offering similar benefits without the risks associated with drugs like Ozempic

*

Glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide — the active ingredient in Ozempic and Wegovy — have taken the world by storm. Originally developed for Type 2 diabetes, these drugs' weight loss properties quickly caught the attention of researchers and the public alike.

Their effectiveness in shedding pounds has led to a global shortage, with an estimated 20 million people using them annually.¹ But as with any quick fix, there's often a catch. According to data from the U.S. Food and Drug Administration's (FDA) Adverse Event Reporting System (FAERS), these medications have been linked to 162 deaths in the U.S.²

The Daily Mail reports that fatalities mentioning weight loss drugs have increased by 40% in just six months, jumping from 117 to 162 reported deaths.³ This sharp rise coincides with the expanding use of these medications, as more formulations hit the market and off-label prescriptions become commonplace.

However, your risk doesn't disappear simply because you're using these drugs as directed. The FAERS data show that adverse reactions occur in patients using these medications for their approved purposes, whether for diabetes management or weight loss.

Ozempic-Related Deaths and ‘Serious’ Reactions on the Rise

The FAERS database reveals a disturbing trend in adverse reactions to weight loss drugs containing semaglutide and tirzepatide (used in Mounjaro and Zepbound). Since 2018, there have been 62,000 reported reactions to these medications in the U.S.⁴

What’s particularly alarming is that 46,000 of these reports — nearly three-quarters of the total — occurred after 2022. This coincides with the increased availability and marketing of these drugs. Of the 162 reported deaths, 94 were linked to semaglutide-based drugs, while 68 were associated with tirzepatide medications. It’s worth noting that in 2023, tirzepatide was linked to nearly twice as many adverse reactions as semaglutide.⁵

The FAERS system has recorded 10,000 “serious” reactions to these weight loss drugs, defined as events resulting in hospitalization or life-threatening conditions. These aren’t just minor inconveniences; they’re significant medical events that could have long-lasting impacts on your health.

For instance, Daily Mail reports a case of a 30-year-old man on Ozempic who was hospitalized with pancreatitis, an inflammation of the pancreas that causes severe abdominal pain. In another case, a 49-year-old woman taking Ozempic experienced mania and a dangerous surge in blood pressure, requiring hospitalization.⁶

While 1.7% of Americans — approximately 5.6 million people — were prescribed weight loss drugs in 2023, recent surveys suggest that number has grown to about 6% of U.S. adults, or 15.5 million people.⁷ This rapid increase in usage means more individuals are exposed to the serious side effects.

Ozempic Linked to Suicidal Ideation

A comprehensive study analyzing the World Health Organization’s database of adverse drug reactions uncovered more troubling findings about Ozempic.⁸ The research, which looked at over 36.1 million reports, found a significant link between semaglutide and suicidal ideation.

Out of 30,527 total reports for semaglutide, 107 cases of suicidal or self-injurious reactions were identified, and the association remained significant even after accounting for other factors. The research revealed a 45% increased risk of suicidal ideation in patients taking semaglutide compared to other medications.⁹

Further, people taking antidepressants or anti-anxiety medications alongside semaglutide were at an even higher risk of reporting suicidal thoughts — a 150% to 300% increase in suicidal ideation was found among this group.¹⁰

A study in *Frontiers in Psychiatry* revealed insights into semaglutide’s impact on your emotional state and psychological well-being.¹¹ The drug’s main component targets GLP-1 receptors, which are present not just in your digestive tract but also in critical brain areas. These regions, such as the lateral septum and hypothalamus, are essential for managing emotions, reward systems and appetite control.

Semaglutide’s interaction with these receptors modifies the functioning of neural pathways

involved in these processes. Particularly noteworthy is its influence on dopamine, a neurotransmitter closely associated with mood regulation and reward perception.

Research indicates that stimulating GLP-1 receptors may enhance dopamine transporter expression, leading to decreased free dopamine levels in specific brain regions. This shift in dopamine signaling might lead to alterations in your mood, motivation levels, and even how you experience pleasure.

Up to 90% of Ozempic Users Experience an Adverse Event

The most common side effects linked to Ozempic and similar drugs are gastrointestinal, including nausea, diarrhea and vomiting. In clinical trials, a staggering 80% to 90% of participants experienced at least one adverse event.¹² Though most were mild to moderate, they led some people to discontinue the medication.

Further, these drugs are intended for long-term use — stopping them often results in weight regain — further increasing the risk of side effects over time. While nausea and diarrhea might seem manageable, more severe health risks, including pancreatitis, are a real concern. A study of 16 million patients found that those taking liraglutide or semaglutide had over nine times the risk of developing pancreatitis compared to those on other weight loss medications.¹³

The same study showed a four-fold increase in the risk of bowel obstruction and nearly four times the risk of gastroparesis (stomach paralysis). Gallbladder issues are another significant concern. Clinical trials revealed higher rates of gallstones and cholecystitis (gallbladder inflammation) in people taking these drugs.¹⁴

While rare, some patients required surgery for these complications. It's also worth noting that these medications increase heart rate.¹⁵ There's also the potential for aspiration during anesthesia. These drugs slow down stomach emptying, which means you may still have food in your stomach even after fasting for the recommended time before surgery. This increases the risk of aspiration pneumonia, a serious complication.

The FDA has also warned that Ozempic causes an intestinal blockage called ileus,¹⁶ which can lead to life-threatening complications if not treated promptly.

Another Ozempic Dark Side: Kidney Damage

Troubling reports of severe kidney problems due to Ozempic are also emerging. Research published in the *Clinical Kidney Journal* reported two patients experienced acute interstitial nephritis (AIN), a serious kidney inflammation, after starting semaglutide.¹⁷

One case even involved focal segmental glomerulosclerosis (FSGS), a type of kidney scarring. These findings suggest these drugs pose significant risks to your kidney health, especially if you have pre-existing kidney issues. The first case involved a 68-year-old woman with chronic kidney disease who started semaglutide for weight loss.

Within weeks, she developed severe nausea and vomiting, leading to a dramatic increase in her creatinine levels — a key indicator of kidney function. Even after stopping the

medication, her kidney function worsened upon restarting it. A biopsy confirmed acute interstitial nephritis, likely triggered by semaglutide.¹⁸

The second case was even more alarming. A 49-year-old woman with no prior kidney issues developed severe swelling and protein in her urine after three months on semaglutide. Her kidney biopsy revealed not only AIN but also FSGS, a condition that can lead to kidney failure.

The study authors suggest that risk factors for these complications may include chronic kidney disease, advanced age, obesity and concurrent use of other medications that can affect the kidneys. A review of the FDA's adverse event reporting system revealed 2,375 kidney-related events associated with GLP-1 drugs between 2010 and 2022.¹⁹

Acute kidney injury was the most common, accounting for nearly 59% of reports. Other reported issues included high blood pressure, electrolyte imbalances and, in rare cases, severe protein loss in the urine.

Akkermansia: A Natural Ozempic Alternative

[Sustainable weight loss](#) involves more than just a quick fix. It requires a holistic approach that considers your overall health, including your mental well-being. As tempting as these drugs might seem, especially with their popularity on social media, it's crucial to make decisions based on scientific evidence rather than anecdotal reports or trends. Your health is too important to gamble with unproven or potentially dangerous solutions.

In my interview with Dr. Colleen Cutcliffe, a molecular biology scientist and the CEO and co-founder of Pendulum, a company that creates microbiome products, she explained that, instead of using Ozempic, you can naturally elevate your GLP-1 levels by increasing the presence of the beneficial bacteria Akkermansia in your gut:

“What happens in your body naturally, if you've got all the right microbes, is that you eat a meal, your microbiome metabolizes that food and generates postbiotics [excretions from beneficial bacteria] like butyrate [and] a protein called P9. Some of these postbiotics then signal your body to produce GLP-1.

All that signaling is happening from the microbiome directly to the L cells. And so you eat a meal, your microbiome digests them, these postbiotics get created and tell your L cells, 'Hey, go produce GLP-1,' and then you get a spike in GLP-1 in your body.

GLP-1 stimulates your body too. It says, 'We've got to metabolize the sugar in the bloodstream, release insulin.' It also signals to your brain, 'We just ate, we're full, we don't need to eat again.' After a period of time, GLP-1 goes down — until the next time you eat a meal. Then it spikes again.

So that's the natural way of things. There are only two strains that have been published, to date, that have been shown to be able to stimulate L cells to produce GLP-1, and one of them is Akkermansia. It actually secretes three different [postbiotics] that stimulate L cells to produce GLP-1.

So, what's been found is that if you are low or missing Akkermansia, your body is not naturally producing as much GLP-1 as it's supposed to be. By giving people back

Akkermansia, you can now have these physiological benefits of reducing A1C and lowering blood glucose spikes.

To be clear, the natural GLP-1 you produce is different from the drug. The drug is a mimic. It's an analog. It looks like GLP-1. It gets injected into the bloodstream directly, which means that rather than the natural spike after you eat [followed by a decline], the [drug] is keeping those levels really high all the time.

So, this signaling of 'we got to metabolize sugar in the blood and we're full, we just ate' is going on constantly. That's why people experience these incredible, amazing overnight effects because that's how those drugs are working. But if you actually have the right microbes, you can generate your body's natural GLP-1 and get back into this natural cycle."

Many People Are Lacking Akkermansia

Research published in Nature Microbiology found that Akkermansia increased thermogenesis and GLP-1 secretion in mice fed a high-fat diet.²⁰ While Akkermansia plays a vital role in maintaining intestinal health, many individuals have insufficient levels due to compromised mitochondrial function and oxygen leakage in the gut.

One of Akkermansia's primary functions is the production of short-chain fatty acids (SCFAs), including butyrate. These fatty acids serve as fuel for your colonocytes, which in turn produce mucin, a gel-like protective substance that coats your gut lining.

SCFAs also help remove oxygen from your colon, creating an environment where beneficial bacteria can flourish. Mucin acts as a barrier, shielding intestinal cells from damage, harmful microorganisms and digestive irritants.

Additionally, mucin enhances your immune system. It contains antibodies and antimicrobial peptides that help fight infections. Mucin also functions as a trap for potential pathogens, facilitating their elimination through the digestive process. [Akkermansia](#) is so beneficial that it should, ideally, constitute about 10% of your gut microbiome.

Make Sure Live Akkermansia Probiotics Reach Your Colon

When selecting Akkermansia probiotics, opt for products with bacterial counts in the billions rather than millions. Generally, a higher bacterial count is beneficial, but there's an important caveat: the delivery method is crucial.

Look for probiotics in delayed-release capsules. This feature is essential because it ensures the beneficial bacteria have a higher likelihood of reaching your colon alive. Without this protective mechanism, most of the bacteria may not survive the journey through your digestive system.

Akkermansia are very sensitive to oxygen. This makes their journey through your digestive system very challenging. These beneficial microbes thrive in an oxygen-free environment, and even a brief exposure to oxygen can be fatal for them. This trait makes the delivery method of Akkermansia supplements crucial to their effectiveness.

In fact, a lower-dose probiotic (in the hundreds of thousands of bacteria) that successfully

reaches your colon can be more effective than a high-dose product (with hundreds of billions of bacteria) that doesn't make it to its intended destination. Remember, when it comes to probiotics, successful delivery to the colon is just as important as the initial dosage.

Understanding this helps you choose the most effective supplement. You want to nurture your gut microbiome with live, active Akkermansia, as dead or inactive ones won't do you as much good as they don't reproduce.

If you want to use Akkermansia supplements, look for ones with advanced, dual-timed release capsules or microencapsulation. These technologies keep Akkermansia dormant and protected until it reaches your colon, usually in two to four hours.

To maximize its effectiveness, take it on an empty stomach, ideally first thing in the morning after an overnight fast. Wait at least one to two hours before eating to reduce transit time, allowing the bacteria to reach your colon faster — usually within two hours. This will greatly increase the number of live bacteria that make it to your colon.

Avoid taking probiotics with food, as this can extend your transit time to over eight hours, likely killing the bacteria long before they reach your colon. Being mindful of when and how you take your Akkermansia probiotic will maximize the benefits of this powerful probiotic.

*

Click the share button below to email/forward this article to your friends and colleagues. Follow us on [Instagram](#) and [Twitter](#) and subscribe to our [Telegram Channel](#). Feel free to repost and share widely Global Research articles.

[Don't Miss Out on Global Research Online e-Books!](#)

Notes

^{1, 8, 9} [JAMA Netw Open. 2024 Aug 20;7\(8\):e2423385](#)

^{2, 3, 4, 5, 6, 7} [Daily Mail September 8, 2024](#)

¹⁰ [ZeroHedge August 21, 2024](#)

¹¹ [Front Psychiatry. 2023 Aug 29;14:1238353](#)

^{12, 13, 14, 15} [Obes Pillars. 2024 Aug 31;12:100127](#)

¹⁶ [U.S. FDA, Drug Safety-related Labeling Changes, Ozempic September 22, 2023](#)

^{17, 18, 19} [Clin Kidney J. 2024 Aug 13;17\(9\):sfae250](#)

²⁰ [Nature Microbiology volume 6, pages 563-573 \(2021\)](#)

Featured image is from MedicalNews Today

The original source of this article is [Mercola](#)
Copyright © [Dr. Joseph Mercola](#), [Mercola](#), 2024

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Dr. Joseph
Mercola](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca
www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca